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Abstract
Purpose To assess safety and effectiveness of anti-tumor necrosis factor (anti-TNF) therapy in IBD patients ≥ 60 years.
Methods Ninety IBD patients ≥ 60 years at initiation of anti-TNF therapy, 145 IBD patients ≥ 60 years without anti-TNF therapy
and 257 IBD patients < 60 years at initiation of anti-TNF therapy were retrospectively included in this multicentre study. Primary
outcome was the occurrence of severe adverse events (SAEs), serious infections and malignancies. Secondary outcome was
effectiveness of therapy. Cox regression analyses were used to assess differences in safety and effectiveness. In safety analyses,
first older patients with and without anti-TNF therapy and then older and younger patients with anti-TNF therapy were assessed.
Results In older IBD patients, the use of anti-TNF therapy was associated with serious infections (aHR 3.920, 95% CI 1.185–
12.973, p = .025). In anti-TNF-exposed patients, cardiovascular disease associated with serious infections (aHR 3.279, 95% CI
1.098–9.790, p = .033) and the presence of multiple comorbidities (aHR 9.138 (1.248–66.935), p = .029) with malignancies,
while patient age did not associate with safety outcomes. Effectiveness of therapy was not affected by age or comorbidity.
Conclusion Older patients receiving anti-TNF therapy have a higher risk of serious infections compared with older IBD patients
without anti-TNF therapy, but not compared with younger patients receiving anti-TNF therapy. However, in anti-TNF-exposed
patients, comorbidity was found to be an indicator with regards to SAEs. Effectiveness was comparable between older and
younger patients.
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Introduction
As a consequence of the aging population and the rising prev-
alence of inflammatory bowel diseases (IBD), the group of
older patients with Crohn’s disease (CD) or ulcerative colitis
(UC) is enlarging. [1] Currently, approximately 10–30% of
IBD patients is > 60 years old and about 10–15% of new
IBD cases is diagnosed in patients > 60 years of age. [2–4]
Safety and effectiveness of medication may differ between
older and younger patients, as a consequence of comorbidity,
polypharmacy, senescence of the immune system or altered
clearance of drugs. [5, 6] Results from clinical trials cannot be
extrapolated to the older patient population with IBD because
these patients are generally excluded from trial participation
and available data from observational studies on the occur-
rence of severe adverse events (SAEs) in older IBD patients
exposed to anti-TNF therapy are inconsistent. [7–10] Besides
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this, previous literature has been focussing on patient age,
rather than comorbidity as a predictor of safety and effective-
ness in patients with IBD receiving anti-tumor necrosis factor
(TNF) therapy.
The aim of the present study is therefore to assess safety
and effectiveness of anti-TNF therapy in patients with IBD




This is a retrospective multicentre cohort study combin-
ing data from five hospitals in the Netherlands
(University Medical Centre Utrecht (UMCU), St.
Antonius Hospital Nieuwegein, Diakonessenhuis
Utrecht, Leiden University Medical Centre (LUMC)
and Maastricht University Medical Centre (MUMC))
on the effect of patient age on safety and effectiveness
of anti-TNF therapy (infliximab (IFX), adalimumab
(ADA) or certolizumab pegol (CZP)). Ethical approval
has been granted by the medical research ethics com-
mittee Leiden The Hague Delft, MREC registration
number G20.057 and research was conducted in accor-
dance with the ethical standards as laid down in the
declaration of Helsinki. Patients with an established
IBD diagnosis were assigned to one of the three
groups.[11] First, patients exposed to anti-TNF therapy
for the first time at ≥ 60 years, second, patients without
any exposure to anti-TNF therapy aged ≥ 60 years and
third, patients < 60 years exposed to anti-TNF therapy.
The following data were collected: age, sex, diagnosis, date
of diagnosis, duration of follow-up, number of IBD-related
hospitalizations and data on anti-TNF therapy and immuno-
suppressive medication. Oral prednisone treatment was docu-
mented if prescribed for a period of at least 6 months at daily
doses of ≥ 7.5 mg. Hepatic comorbidities (steatosis, drug-
induced liver disease, chronic hepatitis B, chronic hepatitis
C and alcoholic liver disease), gastro-intestinal comorbidities
(celiac disease, diverticular disease, ischemic colitis, drug-
induced colitis and radiation enteropathy), cardiovascular co-
morbidities (acute mesenteric ischemia, ischemic heart dis-
ease, cerebrovascular disease and hypertension), pulmonary
comorbidities (asthmatic bronchitis and chronic obstructive
pulmonary disease) and the presence of diabetes were
recorded.
Outcomes
Primary outcome was safety, defined as the occurrence of any
SAE, serious infection or malignancy. Any SAE was defined
as any event that resulted in (prolonging) hospitalization, was
fatal or life-threatening or led to significant disability. Serious
infections were defined similarly. A malignancy was consid-
ered a SAE. In addition, serious infections and malignancies
were analysed separately as safety outcomes. Hospitalization
at start of anti-TNF therapy was not considered a SAE.
Secondary outcome was effectiveness of therapy, de-
fined by duration of anti-TNF therapy and treatment
response, which was categorized as total sustained clin-
ical benefit (primary clinical benefit or secondary clini-
cal benefit, see below) or no sustained clinical benefit.
Patients still receiving anti-TNF therapy at the last day
of follow-up or in whom therapy had been discontinued
because of remission were assigned to the total
sustained clinical benefit group. If anti-TNF therapy
had never been switched to another type of TNF inhib-
itor, total sustained clinical benefit was scored as prima-
ry clinical benefit. Total sustained clinical benefit after
one or more switches of anti-TNF therapy was labelled
secondary clinical benefit. If anti-TNF therapy was
discontinued because of primary non-response, loss of
response, occurrence of an adverse event or any other
reason, patients were classified as having ‘no sustained
clinical benefit’. Primary non-response was defined as
lack of improvement of clinical signs and symptoms
after induction therapy. Loss of response was defined
as recurrence of disease activity during maintenance
therapy after achieving an appropriate induction re-
sponse. [12]
Statistical analysis
All analyses were performed using IBM SPSS Statistics ver-
sion 23.0 (SPSS, Inc, Chicago, IL). For continuous data, de-
scriptive statistics were calculated as means with standard de-
viations (SD) when data were normally distributed and me-
dians with interquartile ranges (IQR) when not normally dis-
tributed. Comparisons between groups were performed using
independent sample t test or Mann-Whitney U test.
Categorical variables were reported using absolute numbers
and percentages, comparisons were performed using the χ2
test or Fisher’s exact test. Cox proportional hazards model was
used to assess the effect of patient age and comorbidity on
primary and secondary outcomes and to assess the effect of
therapy as a time-dependent variable on primary outcome. To
assess whether comorbidity or patient age at start of first anti-
TNF therapy affected effectiveness outcomes, Cox propor-
tional hazards model was used. Safety was defined in three
different outcomes: any SAE, serious infection and malignan-
cy. For any SAE and malignancy analyses, events occurring
until end of follow-up were used. For serious infections,
events occurring up until 3 months after last administration
of medication were used.
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To assess the influence of anti-TNF therapy on the occur-
rence of infections and malignancies as a time-dependent var-
iable, exposure to anti-TNF therapy was tested as a time-
dependent covariate in a Cox proportional hazards model.
Exposure time was defined as time from the first anti-TNF
infusion until the occurrence of a SAE or end of follow-up.
We selected older IBD patients with and without anti-TNF
therapy and used duration of follow-up since date of diagnosis
until end of follow-up as ‘time’ in the malignancy analysis and
follow-up since date of diagnosis until 3 months after the last
date of first anti-TNF therapy or end of follow-up in the in-
fection analysis. Hospitalization of any infection or the diag-
nosis of any malignancy was used as ‘status’. In the analyses
regarding malignancies, the covariates age, comorbidity (cat-
egorized in no comorbidity, one comorbidity and two or more
comorbidities, or specified in cardiovascular disease and dia-
betes), use of immunosuppressive therapy (oral prednisone
and MTX/thiopurine use), use of budesonide and use of
anti-TNF therapy were used. In the analysis regarding serious
infections, immunosuppressive therapy was not used as a co-
variate because a cut-off follow-up duration was applied and
start and stop dates of immunosuppressive therapy had not




We identified 347 IBD patients currently using anti-
TNF therapy, of whom 90 were 60 years or older at
initiation of anti-TNF therapy and of whom 257 patients
were younger than 60 years at the start of anti-TNF
therapy. An additional 145 anti-TNF naive IBD patients
of 60 years or older served as controls. The first group
of patients was included in the hospitals UMCU
(24.4%), St. Antonius Hospital Nieuwegein (16.7%),
Diakonessenhuis Utrecht (5.6%), LUMC (17.8%) and
MUMC (35.7%). Patients from group 2 were included
in the hospitals UMCU (81.7%), Sint Antonius Hospital
Nieuwegein (1.9%), Diakonessenhuis Utrecht (4.7%),
LUMC (4.3%) and MUMC (7.4%). Patients in group
3 were included in UMCU (99.3%) and LUMC
(0.7%). Characteristics of these patients are shown in
Table 1.
Older patients receiving anti-TNF therapy less often had
CD compared with patients receiving anti-TNF therapy at a
younger age. The older patients more often had diabetes,
gastro-intestinal, cardiovascular and other comorbidities and
less often used MTX or thiopurine therapy compared with
younger patients with anti-TNF therapy (87.8% versus
96.1%, p < .010). Patients in the anti-TNF naive group were
diagnosed at a younger age when compared with the older
patients on anti-TNF therapy. Anti-TNF naive patients dif-
fered from the older patients on anti-TNF therapy with respect
to diagnosis (less CD, more UC) and the use of immunosup-
pressive therapy (less thiopurines orMTX). Comorbidity rates
were similar between older IBD patients with and without
anti-TNF therapy.
Does anti-TNF therapy influence the occurrence of
safety outcomes in older patients?
To assess the effect of anti-TNF therapy on safety outcomes in
older patients, all older patients were analysed using date of
diagnosis as start of follow-up, with the use of anti-TNF ther-
apy as a time-dependent covariate.
Twenty-eight serious infections occurred during fol-
low-up. Use of anti-TNF therapy was found to increase
risk of serious infections (aHR 3.920, 95% CI 1.185–
12.973, p = .025) in multivariable Cox regression. Age
at diagnosis, number of comorbidities (Table 2) and the
presence of cardiovascular disease or diabetes (data not
shown) did not affect the risk of serious infections.
Twenty-six malignancies occurred during follow-up.
Univariable and multivariable Cox regression analysis did
not show an association between the use of anti-TNF therapy
and the development of malignancies during follow-up (Table
3). The presence of the comorbidities diabetes or cardiovas-
cular disease was also not associated with occurrence of ma-
lignancies (data not shown). Infections and malignancies are
presented in supplementary Tables 1 and 2.
Do patient age or comorbidity affect the safety of
anti-TNF therapy
To assess the effect of patient age and comorbidity on safety
outcomes in anti-TNF therapy, all anti-TNF-exposed patients
were analysed. One hundred and eighteen SAEs (any SAE) oc-
curred after start of first anti-TNF therapy, the majority (46,
40.0%) because of exacerbation of disease and 26 (22.3%) be-
cause of IBD-related surgery. Age at start of anti-TNF therapy
and comorbidity were not associated with the occurrence of any
SAE (supplementary Table 3a). The incidence of IBD-related
surgery did not differ between older and younger anti-TNF users
(5 out of 90 patients (5.6%) versus 21 out of 257 (8.2%), p =
0.417).
Twenty serious infections occurred after start of anti-TNF
therapy, but age did not affect the risk of occurrence. The
presence of cardiovascular disease was independently associ-
ated with the occurrence of serious infections (aHR 3.279,
95% CI 1.098–9.790, p = .033), whereas presence of diabetes
or the presence of any comorbidity was not (supplementary
Table 3b).
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Eight malignancies were diagnosed after start of anti-TNF
therapy, age was not a risk factor (supplementary Tables 3c).
The presence of two or more comorbidities was independently
associated with the risk of developing a malignancy (aHR
9.138, 95% CI 1.248–66.935, p = .029, supplementary
Table 3c). A list of all SAEs occurring after start of first
anti-TNF therapy is presented in supplementary Tables 4, 5
and 6.
Table 1 Characteristics of study population
Older patients with anti-
TNF therapy (n = 90)
Older patients without anti-
TNF therapy (n = 145)
Younger patients with anti-
TNF therapy (n = 257)
Age at inclusion in years, median [IQR] 68.72 [66.74–73.00] 69.44 [65.01–75.02] 37.43 [27.72–20.24]***
Male, n (%) 49 (54.4) 84 (57.9) 121 (47.1)
Age at diagnosis, mean (±SD) 52.15 (16.10) 46.39 (15.75)** 26.16 (11.27)***
Age at start anti-TNF therapy, mean (±SD) 67.56 (6.00) n.a. 34.18 (12.94)***
Disease duration in years, median [IQR] 16.67 [5.73–29.48] 21.31 [12.04–34.14]** 10.14 [5.58–18.23]*
Duration of FU in weeks (start first anti-TNF till end
FU or stop therapy) median [IQR]
70.50 [34.00–155.25] n.a. 110.00 [41.50–217.00]*
Duration of FU in months (date diagnosis till
malignancy or end FU), median [IQR]
194.00 [66.00–322.50] 249.00 [144.00–396.00] n.a.
Duration of total anti-TNF therapy in years, median
[IQR]
1.72 [0.81–4.04] n.a. 3.34 [1.44–5.41]***
Type of IBD, n (%)
CD 56 (62.2) 67 (46.2)** 206 (80.2)**
UC 30 (33.3) 71 (49.0)** 44 (17.1)**
IBD-U/IC 4 (4.4) 7 (4.8) 7 (2.7)
Montreal classification, n (%)
CD location L1/L2/L3/L4 11 (19.6)/18 (32.1)/26
(46.2)/ 1 (1.8)




CD behaviour B1/B2/B3 19 (34.5)/26 (47.3)/10
(18.2)
36 (53.7)/17 (25.4)/14 (20.9)* 81 (39.5)/68 (33.2)/56 (27.3)
Perianal disease 21 (41.1) 10 (15.2)** 85 (43.4)
UC extension E1/E2/E3 0 (0.0)/14 (45.2)/17 (54.8) 2 (2.9)/29 (42.6)/37(54.4) 1 (2.2)/12 (26.7)/32 (71.1)
Comorbidity, n (%)
Hepatic 6 (6.7) 14 (9.7) 8 (3.1)
Gastrointestinal 19 (21.1) 28 (19.3) 6 (2.3)***
Cardiovascular 35 (38.9) 74 (51.0) 34 (13.2)***
Pulmonary 10 (11.1) 18 (12.4) 18 (7.0)
Diabetes mellitus 14 (15.7) 18 (12.4) 12 (4.7)**
Comorbidity, n (%)
No comorbidity 35 (38.9) 47 (32.4) 191 (74.3)***
One comorbidity 33 (36.7) 55 (37.9) 54 (21.0)
Two or more comorbidities 22 (24.4) 43 (29.7) 12 (4.7)
Type of TNF-inhibitor, n (%)
IFX 67 n.a. 220*
ADA 44 129
CZP 0 (0.0) 5
Immunosuppressant, n (%)
Thiopurines/MTX 79 (87.8) 51 (35.4)*** 247 (96.1)**
Older inflammatory bowel disease (IBD) patients (≥ 60 years) at initiation of anti-tumor necrosis factor (anti-TNF) therapy were compared with older
IBD patients (≥ 60 years) without any anti-TNF therapy and with younger IBD patients aged < 60 years at initiation of anti-TNF therapy. Significant
differences are shown. ***p < .001, **p < .01, *p < .05
IQR interquartile range, SD standard deviation, FU follow-up, CD Crohn’s disease, UC ulcerative colitis, IBD-U IBD unclassified, IC indeterminate
colitis, IFX infliximab, ADA adalimumab, CZP certoluzimab pegol, MTX methotrexate
L4 was reported when only upper gastrointestinal (GI) disease was present, CD location was missing inN = 1 (group 3), CD behaviour was missing inN
= 1 (group 1) andN = 1 (group 2), perianal disease was missing inN = 5 (group 1),N = 10 (group 2) andN = 1 (group 3), UC extension was missing inN
= 3 (group 1),N = 6 (group 2) andN = 10 (group 3). The use ofMTXwasmissing inN = 1 in the group with older IBD patients without anti-TNF therapy
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Do patient age or comorbidity affect the effectiveness
of anti-TNF therapy?
The clinical effectiveness of anti-TNF therapy did not differ be-
tween older and younger anti-TNF users (Table 4) or between
patients with and without comorbidity. Follow up, defined as the
time from first anti-TNF administration until discontinuation of
therapy, was significantly shorter in the group of older patients
compared with younger patients (median duration 70.5 weeks
(34.0–155.3) versus 110.0 weeks (41.5–217.0), p = .017,
Table 4). Follow-up did not differ between patients with and
without comorbidity (median duration 114.0 weeks (47.0–
221.0) versus 92.0 weeks (35.0–200.5), p = .161). When using
Cox regression analysis, age at start of anti-TNF therapy, comor-
bidity and type of anti-TNF therapy did not affect duration of
treatment (Table 5). The presence of diabetes or cardiovascular
disease during follow-up did not significantly affect the duration
of treatment as well (data not shown).
The number of older patients discontinuing anti-TNF ther-
apy because of adverse events was significantly higher com-
pared with younger patients (55.9% versus 28.1%, p = .003,
Table 4) while the number of older patients stopping because
of loss of responsewas significantly lower (26.5% versus 59.5%,
p = .001, Table 4). The number of patients with comorbidity
discontinuing anti-TNF therapy because of adverse events was
significantly higher compared with patients without comorbidity
(47.1% versus 27.9%, p = .018). The number of patients with
comorbidity stopping because of loss of response was lower as
compared with patients without comorbidity, although this did
not differ significantly (43.1% versus 56.7%, p = .111). Reasons
for stopping are presented in supplementary Table 7.
Discussion
In this multicentre study, we found that the presence of co-
morbidity was a better indicator of serious infections and ma-
lignancies in anti-TNF-exposed patients than patient age.
Effectiveness of anti-TNF therapy was comparable between
older and younger patients. Reasons for cessation of therapy
did differ, being more often due to adverse events in older
patients and patients with comorbidity.
In our study, exposure to anti-TNF treatment increased the
risk of serious infections in older patients with IBD. In the
Table 2 Univariable and
multivariable analysis on the
occurrence of serious infections in
older anti-TNF users and older
non-users, using follow-up time
from date of diagnosis until 3
months after last administration of
anti-TNF therapy or end of fol-
low-up
Univariable analysis Multivariable analysis
HR 95% CI P HR 95% CI P
Anti-TNF therapy 5.131 1.679–15.684 0.004 3.920 1.185–12.973 0.025
Age at diagnosis 1.026 0.997–1.057 0.078 1.018 0.987–1.049 0.264
Comorbiditya
1 1.308 0.550–3.112 0.544 1.164 0.487–2.785 0.733
2 or more 1.202 0.445–3.247 0.717 0.999 0.363–2.751 0.998
HR hazard ratio, CI confidence interval, TNF tumor necrosis factor
a Reference is zero comorbidities
Table 3 Univariable and
multivariable analysis on the
occurrence of malignancies in
older anti-TNF users and older
non-users, using follow-up time
from date of diagnosis until end of
follow-up
Univariable analysis Multivariable analysis
HR 95% CI P HR 95% CI P
Anti-TNF therapy 2.617 0.770–8.894 0.123 1.422 0.284–7.128 0.668
Age at diagnosis 1.046 1.010–1.082 0.011 1.025 0.989–1.063 0.178
Comorbiditya
1 3.248 1.058–9.971 0.040 2.706 0.844–8.683 0.094
2 or more 4.036 1.238–13.156 0.021 2.869 0.809–10.183 0.103
Budesonide 1.681 0.771–3.663 0.191 1.746 0.758–4.018 0.190
Oral prednisone 0.721 0.287–1.815 0.488 1.012 0.365–2.802 0.982
MTX and/or thiopurine use 0.700 0.321–1.527 0.270 0.630 0.245–1.621 0.338
HR hazard ratio, CI confidence interval, TNF tumor necrosis factor, MTX methotrexate
a Reference is zero comorbidities
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Treat registry, an increase in serious infections was observed
in anti-TNF-treated IBD patients. [13] Lobaton et al. found a
higher incidence of serious infections in patients aged ≥ 65
years on anti-TNF therapy as compared with older patients
using immunosuppressive medication and/or corticosteroids.
[8] More recently, two meta-analyses were published
assessing safety risks of biologics in older patients with
IBD. Both Piovani et al. (RR 2.70, 95% CI 1.56–4.66, serious
infections) and Borren and Ananthakrishnan (OR 11.22; 95%
CI 3.60–34.99, any infection) found that the risk of infections
was substantially increased when comparing older anti-TNF
users to older non-users.[14, 15]
When comparing younger to older patients, we used age at
start of follow-up as a factor in multivariate analysis instead of
using an arbitrary cut-off at 60 or 65 years of age. As ageing is
a gradual process with a steady reduction of physiologic
Table 4 Treatment response in






First anti-TNF therapy, n (%)
IFX 59 (65.6) 199 (77.4) 0.035
ADA 31 (34.4) 58 (22.6)
First anti-TNF treatment duration in weeks,
median [IQR]
70.50 [34.00–155.25] 110.00 [41.50–217.00] 0.017
Stop date of first anti-TNF therapy n (%) 0.004
Year < 2005 0 (0,0) 14 (11.0)
Year 2005–2009 6 (17.1) 46 (36.2)
Year ≥ 2010 29 (82.9) 67 (52.8)
Total sustained clinical benefit 73 (81.1) 201 (78.2) 0.653
Primary clinical benefit 55 (61.1) 133 (51.8) 0.141
Secondary clinical benefit 18 (20.0) 68 (26.5) 0.257
Stop reasons for first anti-TNF treatment, n (%)
Primary non-responder 1 (2.9) 5 (4.7) 1.000
Secondary loss of response 9 (26.5) 72 (59.5) 0.001
Adverse event 19 (55.9) 34 (28.1) 0.004
Other 5 (14.7) 10 (8.3) 0.323
Treatment response compared between patients on anti-TNF therapy aged ≥ 60 years and aged < 60 years. Stop
date of first anti-TNF therapy: the year in which the first anti-TNF therapy was stopped. Total sustained clinical
benefit: still receiving anti-TNF therapy at last day of FU or anti-TNF therapy discontinuation because of
remission. Primary clinical benefit: no switch to other anti-TNF therapy during FU and still receiving anti-TNF
therapy at last day of FU or discontinuation of remission of disease. Secondary clinical benefit: clinical benefit
after one or more switches of anti-TNF therapy. Primary non-responder: lack of improvement of clinical signs and
symptoms after induction therapy. Secondary loss of response: recurrence of disease activity during maintenance
therapy after achieving an appropriate induction response. Percentages per stop reason were calculated as per-
centage of all stop reasons per group
TNF tumor necrosis factor, IQR interquartile range, IFX infliximab, ADA adalimumab, FU follow-up
Table 5 Univariable and
multivariable analysis on duration
of first anti-TNF treatment
Univariable analysis Multivariable analysis
HR 95% CI P HR 95% CI P
Age at start therapy 0.999 0.991–1.008 0.906 1.000 0.990–1.010 0.966
Comorbiditya
1 0.739 0.501–1.088 0.126 0.731 0.484–1.104 0.137
2 or more 1.130 0.676–1.887 0.642 1.130 0.635–2.012 0.678
Type of anti-TNF therapyb 1.087 0.753–1.568 0.657 1.114 0.767–1.620 0.570
HR hazard ratio, CI confidence interval, TNF tumor necrosis factor
a Reference is zero comorbidities
b Reference is infliximab therapy (certolizumab pegol was not used as first anti-TNF therapy)
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reserves, this strategy may be a better way to evaluate the role
of ageing on occurrence of serious infections and malignan-
cies. In our study, patient age did not affect the occurrence of
SAEs, serious infections and malignancies. However, pres-
ence of cardiovascular disease did increase the risk of serious
infections, and the presence of multiple comorbidities in-
creased the risk of developing a malignancy. These findings
are in contrast to those of the Borren and Ananthakrishnan
meta-analysis, in which older patients had a higher risk of
malignancy (OR, 3.47; 95% CI, 1.71–7.03) and infection
(OR, 3.48; 95% CI, 1.98–6.14). This may be due to the fact
that the patients in a number of these studies were older [16,
17] and may have had more comorbidities. Especially this
latter factor may be important as studies on toxicity of chemo-
therapy found that comorbidity increases the risk for toxicity
and is a better indicator for toxicity risk than patient age.[16,
17] Previous studies found that presence of comorbidities in-
creased the risk for adverse events in response to immunosup-
pressive treatments. [18, 19]
Desai et al. concluded that older IBD patients were less
likely to respond to anti-TNF therapy and had a shorter
drug survival as compared with younger patients. Among
both patient groups, comorbidity (Charlson Comorbidity
Index (CCI) > 0) was associated with anti-TNF therapy
discontinuation. This could be due to polypharmacy com-
bined with altered drug absorption, distribution and elimi-
nation [20] or due to an increased opportunity for drug
interactions because of polypharmacy for multiple morbid-
ities. [21] In line with a recent study on persistence of anti-
TNF therapy in older patients with IBD by Porcari et al.
[22], we observed a shorter treatment duration in older
patients compared with younger patients. However, when
analysing both patient groups together using Cox regres-
sion analysis and correcting for confounders, age at start of
therapy did not affect treatment duration. Older patients
did discontinue therapy more frequently due to adverse
events, and less often due to loss of response, as compared
with younger patients. This has also been described by
Desai et al.[7] Both our results and the study by Porcari
et al. did not find comorbidity to affect time to cessation of
anti-TNF therapy while Desai et al. found increasing co-
morbidity to be associated with treatment cessation.[7]
Regarding effectiveness, Lobaton et al. only found a re-
duced short-term response to anti-TNF therapy in older
patients, but this difference disappeared after 6 months. [8]
Our study has some limitations, in addition to those inher-
ent to any study with a retrospective design. Clinical activity
scores were not available, as a result of which data on clinical
treatment response were based on comments in medical re-
ports instead of disease activity scores. Comorbidity scores
were based on the sum of comorbidities because information
to calculate a comorbidity score such as the CCI was not fully
available. However, because data in all patients were obtained
from medical reports, reporting bias would have affected all
patients equally. Furthermore, younger patients exposed to
anti-TNF therapy were mostly (93.4%) included in referral
centres and the older non-anti-TNF users were included in
referral hospitals only. One could argue that this could have
affected comparability of patients, although we assume that in
all hospitals, international guidelines considering anti-TNF
therapy are maintained, especially concerning reasons to stop
therapy. The older non-anti-TNF users, although included in a
referral centre, had a milder disease compared with older anti-
TNF users, as expressed by the infrequent use of immuno-
modulatory medication in this group during follow-up.
The strength of our study lies in the large number of pa-
tients included and the multicentre aspect; patients were in-
cluded from three referral hospitals and two general hospitals.
We believe that our study therefore provides reliable and gen-
eralizable data on the effect of anti-TNF compounds in older
patients with IBD.
In conclusion, this study shows that the presence of comor-
bidities, and not an increasing age, is a risk factor for SAEs in
IBD patients on anti-TNF therapy. Older patients receiving
anti-TNF therapy have a higher risk of serious infections com-
pared with older IBD patients without anti-TNF therapy, but
not compared with younger IBD patients receiving anti-TNF
therapy. Effectiveness of therapy was comparable between
older and younger patients but older patients tend to stop
therapy more often because of adverse events and less often
due to loss of response compared with younger patients.
Careful monitoring of the older IBD patient with multiple
comorbidities receiving anti-TNF therapy is recommended.
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